An official website of the United States government
Beat Childhood Cancer Specimen Banking and Data Registry
Trial Status: active
This is an observational data registry study of pediatric cancer patients at
participating Beat Childhood Cancer Consortium sites involving specimen banking and data
collection.
Inclusion Criteria
No age restrictions
Subjects that fit into one of the following categories:
Subjects with suspected or confirmed cancers of childhood, adolescence, or young adulthood.
Survivors of a cancer of childhood, adolescence, or young adulthood (> 6 months off last therapy for cancer)
Subjects with a disease-matched condition
Healthy volunteers- including any participants with medical conditions that are not disease-matched.
Written informed consent in accordance with institutional and FDA guidelines must be obtained from all subjects (or subjects' legal representative).
Exclusion Criteria
Subject or his/her legally authorized representative (where applicable) did not consent for specimen banking and data collection for this study.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT04715178.
Locations matching your search criteria
United States
Iowa
Iowa City
University of Iowa/Holden Comprehensive Cancer Center
Status: Active
Name Not Available
North Carolina
Winston-Salem
Wake Forest University Health Sciences
Status: Active
Name Not Available
This observational registry and banking study is being performed on a large cohort of
subjects who have received molecular testing to better understand the relationship
between genomic and molecular information and clinical outcomes, and to enable timely and
informed treatment decisions by physicians for their cancers. We hypothesize that large
gene panels, sequencing (DNA/RNA), and epigenetics of tumors can identify molecular
aberrations that can be leveraged to offer more effective treatment. Findings may
highlight additional areas of research required to better understand the molecular
underpinnings of the relationship between molecular abnormalities and disease. Banked
specimens and the creation of tumor cell lines and xenograft models will facilitate
further advancement of this research.
Trial PhaseNo phase specified
Trial TypeNot provided by clinicaltrials.gov
Lead OrganizationGiselle Sholler
Principal InvestigatorGiselle Linda Saulnier Sholler
